Document Detail


The development of proteasome inhibitors as anticancer drugs.
MedLine Citation:
PMID:  15144949     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The ubiquitin-proteasome pathway plays a central role in the targeted destruction of cellular proteins, including cell cycle regulatory proteins. Because these pathways are critical for the proliferation and survival of all cells, and in particular cancerous cells, proteasome inhibition is a potentially attractive anticancer therapy. Based on encouraging cytotoxic activity, bortezomib was the first proteasome inhibitor to be evaluated in clinical trials. Efficacy and safety results from a phase 2 clinical trial contributed to approval of bortezomib for use in patients with relapsed and refractory multiple myeloma who have received at least 2 prior therapies and have demonstrated disease progression on their last therapy.
Authors:
Julian Adams
Related Documents :
20082139 - E1a oncogene expression inhibits pthrp p3 promoter activity and sensitizes human prosta...
17291459 - Effects of hydroxyl radical scavenging on cisplatin-induced p53 activation, tubular cel...
19325839 - Prodrugs of fluoro-substituted benzoates of egc as tumor cellular proteasome inhibitors...
12752669 - Regulation of apoptosis by ubiquitination.
9713489 - Evaluation of apoptosis in four human tumour cell lines with differing sensitivities to...
19034669 - Calpain and proteasomal regulation of antiretroviral zinc finger protein otk18 in human...
21890409 - 'necrosome'-induced inflammation: must cells die for it?
24441789 - The unfolded-protein-response sensor ire-1α regulates the function of cd8α(+) dendrit...
21285529 - Autophagy and apoptosis are redundantly required for c. elegans embryogenesis.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Cancer cell     Volume:  5     ISSN:  1535-6108     ISO Abbreviation:  Cancer Cell     Publication Date:  2004 May 
Date Detail:
Created Date:  2004-05-17     Completed Date:  2004-06-28     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  101130617     Medline TA:  Cancer Cell     Country:  United States    
Other Details:
Languages:  eng     Pagination:  417-21     Citation Subset:  IM    
Affiliation:
Infinity Pharmaceuticals, Inc., 780 Memorial Drive, Cambridge, MA 02139, USA. julian.adams@ipi.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents / therapeutic use*
Boronic Acids / therapeutic use*
Clinical Trials as Topic
Humans
Multiple Myeloma / drug therapy*
Protease Inhibitors / therapeutic use*
Pyrazines / therapeutic use*
Ubiquitins / metabolism
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Boronic Acids; 0/Protease Inhibitors; 0/Pyrazines; 0/Ubiquitins; 0/bortezomib

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Predictive factors for epidermal growth factor receptor inhibitors--the bull's-eye hits the arrow.
Next Document:  Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, fr...